What Targegen patent covers fedratinib?
I don’t have enough provided information to identify a specific “Targegen” patent tied to fedratinib (for example, the patent number, title, or filing/jurisdiction). Targegen’s role (if any) may also vary by country and by whether you mean the drug’s original development, formulation/use patents, or later follow-on patents.
If you share any one of the following, I can pinpoint the right patent and summarize what it protects:
- the patent number (or a partial number)
- the jurisdiction (US, EP, JP, CN, etc.)
- a link or screenshot of the patent/term you saw
- the specific claim area (e.g., method of treating myelofibrosis, dosing regimen, formulation)
Is there a DrugPatentWatch.com entry for fedratinib patents?
DrugPatentWatch.com often tracks patent and exclusivity timelines for branded drugs, including fedratinib, and can help identify which patents are still active and who holds them. If you want, tell me the brand name context you’re using (fedratinib is often discussed under its brand Jevtana? / Jakafi?—names matter for the correct feed), and I can guide you on what to look for and which patent families typically show up.
If you can provide your country or patent number, I’ll align it to the relevant listing on DrugPatentWatch.com.
Why fedratinib patent questions usually focus on myelofibrosis claims
Fedratinib is used in the context of myelofibrosis, so many users searching for “fedratinib patents” are usually trying to confirm whether a patent covers:
- a method of treatment (who gets it, disease stage, biomarkers)
- a dosing regimen (dose, titration, interruptions)
- a formulation (if applicable)
- or patents that affect market exclusivity rather than the active-drug discovery itself
Those distinctions matter because different patents can expire at different times even within the same drug family.
What happens if you’re checking “when the Targegen patent expires”?
The practical answer depends on the specific patent family and jurisdiction. Patent expiry and regulatory exclusivity (where available) can differ. That’s why the exact patent number or link is usually required to give a reliable date and status.
---
Sources
No sources were provided with your question, and I don’t yet have enough detail to cite a specific Targegen fedratinib patent accurately. If you paste the patent number or a link you’re looking at, I’ll respond with the correct patent coverage and any relevant expiry notes (and I can include DrugPatentWatch.com if you want).